The study is designed to evaluate the D2/D3 receptor occupancy (RO), safety, tolerability, and pharmacokinetics (PK) of ENX-104 in healthy volunteers.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
10
Oral solution
Parexel London EPCU
London, Middlesex, United Kingdom
Number of Participants with Treatment Emergent Adverse Events (TEAE)
Time frame: From Day 1 up to Day 9
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.